Circulating Vitamin D in relation to cancer incidence and survival of the head and neck and oesophagus in the EPIC cohort

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Fanidi, Anouar ^a   Muller, David C ^a   Midttun, Øivind ^b   Ueland, Per Magne ^c,d   Vollset, Stein Emil ^c,e   Relton, Caroline ^f   Vineis, Paolo ^g,h   Weiderpass, Elisabete ⁱ   Skeie, Guri ⁱ   Brustad, Magritt ⁱ   Palli, Domenico ^j   Tumino, Rosario ^k   Grioni, Sara ^l   Sacerdote, Carlotta ^m   Bueno De Mesquita, H B ^n,o   Peeters, Petra H ^o   Boutron Ruault, Marie Christine ^p,q,r   Kvaskoff, Marina ^p,q,r   Cadeau, Claire ^p,q,r   Huerta, José María ^s,t   Sánchez, Maria José ^s,u   Agudo, Antonio ^v   Lasheras, Cristina ^w   Quirós, J Ramón ^x   Chamosa, Saioa ^g   Riboli, Elio ^g   Travis, Ruth C ^y   Ward, Heather ^g   Murphy, Neil ^g   Khaw, Kay Tee ^z   Trichopoulou, Antonia ^aa,ab   Lagiou, Pagona ^aa,ac,ad   Papatesta, Eleni Maria ^ab   Boeing, Heiner ^ae   Kuehn, Tilman ^af   Katzke, Verena ^af   Steffen, Annika ^ae   Johansson, Anders ^af   Brennan, Paul ^a   Johansson, Mattias ^a   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b BEVITAL AS   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h HuGeF Foundation   (Italy)

ⁱ UNIVERSITY OF TROMSØ   (Norway)

^j CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^k Civile MP Arezzo Hospital   (Italy)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m HuGeF Foundation and CPO Piemonte   (Italy)

ⁿ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^o UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^p CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^q UNIVERSITÉ PARIS SACLAY   (France)

^r INSTITUT GUSTAVE ROUSSY   (France)

^s CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^t ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^u CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^v UNIVERSITY OF OVIEDO   (Spain)

^w PUBLIC HEALTH DIRECTORATE   (Spain)

^x BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^y UNIVERSITY OF OXFORD   (United Kingdom)

^z HELLENIC HEALTH FOUNDATION   (Greece)

^aa UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^ab HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ac BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^ad GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^ae GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^af UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE EXACERBATION; ESOPHAGUS TUMOR; EUROPE; FEMALE; HEAD AND NECK TUMOR; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; CALCIFEDIOL; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; EUROPE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84994635746     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36017     Document Type: Article

References (29)

1. Ferlay, J. S. I., Ervik, M. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, http:// globocan.iarc.fr (2013).
2. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization. International Agency for Research on Cancer 83, 1-1438 (2004).
3. Alcohol consumption and ethyl carbamate. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization. International Agency for Research on Cancer 96, 3-1383 (2010).
4. Chaturvedi, A. K. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29, 4294-4301, doi: 10.1200/JCO.2011.36.4596 (2011).
5. Holick, M. F. Vitamin D deficiency. The New England journal of medicine 357, 266-281, doi: 10.1056/NEJMra070553 (2007).
6. Mehta, R. G. & Mehta, R. R. Vitamin D and cancer. The Journal of nutritional biochemistry 13, 252-264 (2002).
7. Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E. & Feldman, B. J. The role of vitamin D in reducing cancer risk and progression. Nature reviews. Cancer 14, 342-357, doi: 10.1038/nrc3691 (2014).
8. Deeb, K. K., Trump, D. L. & Johnson, C. S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature reviews. Cancer 7, 684-700, doi: 10.1038/nrc2196 (2007).
9. Jenab, M. et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 340, b5500, doi: 10.1136/bmj.b5500 (2010).
10. Ma, Y. et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29, 3775-3782, doi: 10.1200/JCO.2011.35.7566 (2011).
11. Skaaby, T. et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 23, 1220-1229, doi: 10.1158/1055-9965.EPI-14-0007 (2014).
12. Afzal, S., Bojesen, S. E. & Nordestgaard, B. G. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clinical chemistry 59, 771-780, doi: 10.1373/clinchem.2012.201939 (2013).
13. Arem, H. et al. Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20, 1178-1184, doi: 10.1158/1055-9965.EPI-11-0153 (2011).
14. Abnet, C. C. et al. Circulating 25-hydroxyvitamin D and risk of esophageal and gastric cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. American journal of epidemiology 172, 94-106, doi: 10.1093/aje/kwq121 (2010).
15. Konety, B. R. et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. The Journal of urology 165, 253-258, doi: 10.1097/00005392-200101000-00074 (2001).
16. Mantell, D. J., Owens, P. E., Bundred, N. J., Mawer, E. B. & Canfield, A. E. 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circulation research 87, 214-220 (2000).
17. Meier, J. D. et al. Treatment with 1-alpha, 25-dihydroxyvitamin D3 (vitamin D3) to inhibit carcinogenesis in the hamster buccal pouch model. Archives of otolaryngology-head & neck surgery 133, 1149-1152, doi: 10.1001/archotol.133.11.1149 (2007).
18. Mernitz, H., Smith, D. E., Wood, R. J., Russell, R. M. & Wang, X. D. Inhibition of lung carcinogenesis by 1alpha, 25-dihydroxyvitamin D3 and 9-cis retinoic acid in the A/J mouse model: evidence of retinoid mitigation of vitamin D toxicity. International journal of cancer. Journal international du cancer 120, 1402-1409, doi: 10.1002/ijc.22462 (2007).
19. Nakagawa, K., Sasaki, Y., Kato, S., Kubodera, N. & Okano, T. 22-Oxa-1alpha, 25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26, 1044-1054, doi: 10.1093/carcin/bgi049 (2005).
20. Ordonez-Moran, P. et al. Vitamin D and cancer: an update of in vitro and in vivo data. Frontiers in bioscience: a journal and virtual library 10, 2723-2749 (2005).
21. McCullough, M. L. et al. Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. American journal of epidemiology 172, 21-35, doi: 10.1093/aje/kwq113 (2010).
22. Jones, A. S. et al. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 75, 1343-1353 (1995).
23. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA: a cancer journal for clinicians 55, 74-108 (2005).
24. Pulte, D. & Brenner, H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. The oncologist 15, 994-1001, doi: 10.1634/theoncologist.2009-0289 (2010).
25. Riboli, E. et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public health nutrition 5, 1113-1124, doi: 10.1079/PHN2002394 (2002).
26. Johansson, M. et al. Circulating biomarkers of one-carbon metabolism in relation to renal cell carcinoma incidence and survival. Journal of the National Cancer Institute 106, doi: 10.1093/jnci/dju327 (2014).
27. Midttun, O. & Ueland, P. M. Determination of vitamins A, D and E in a small volume of human plasma by a high-throughput method based on liquid chromatography/tandem mass spectrometry. Rapid communications in mass spectrometry: RCM 25, 1942-1948, doi: 10.1002/rcm.5073 (2011).
28. Royston, P. & Parmar, M. K. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statistics in medicine 21, 2175-2197, doi: 10.1002/ sim.1203 (2002).
29. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/ (2013).